[Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy].
Biliary tract cancers, including extrahepatic bile duct cancer, are often diagnosed at an advanced stage; however,no standard therapies have been established as yet for this disease,and new,effective chemotherapeutic agents are being sought. Recently, a late phase II study of S-1, an oral fluoropyrimidine, in 40 patients with advanced biliary tract cancer yielded a good response rate of 35.0%. In this article,we report two patients with advanced extrahepatic bile duct cancer enrolled in the study who showed a partial response to S-1 monotherapy.
Ueno
Hideki
H
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital.
Ikeda
Masafumi
M
D000230:Adenocarcinoma / Q000188:drug therapy*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001650:Bile Duct Neoplasms / Q000188:drug therapy*; D017734:Bile Ducts, Extrahepatic; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage*; D011788:Quality of Life; D005641:Tegafur / Q000008:administration & dosage*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid